There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ATAI Life Sciences (ATAI – Research Report), Halozyme (HALO – Research Report) and Natera (NTRA – Research Report) with bullish sentiments.
ATAI Life Sciences (ATAI)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on ATAI Life Sciences on January 19 and set a price target of $20.00. The company’s shares closed last Monday at $1.79.
According to TipRanks.com, Trucchio is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
ATAI Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.
See today’s best-performing stocks on TipRanks >>
Halozyme (HALO)
Benchmark Co. analyst Robert Wasserman maintained a Buy rating on Halozyme on January 19 and set a price target of $50.00. The company’s shares closed last Monday at $34.06.
According to TipRanks.com, Wasserman is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Halozyme with a $48.89 average price target, which is a 42.7% upside from current levels. In a report issued on January 4, Wells Fargo also maintained a Buy rating on the stock with a $52.00 price target.
Natera (NTRA)
Piper Sandler analyst David Westenberg assigned a Buy rating to Natera on January 17 and set a price target of $70.00. The company’s shares closed last Monday at $66.11, close to its 52-week high of $68.59.
According to TipRanks.com, Westenberg is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Natera with a $72.80 average price target, representing a 6.8% upside. In a report issued on January 9, Leerink Partners also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATAI:
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Atai Life Sciences announces strategic investment in Beckley Psytech
- atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
- Atai Life Sciences announces topline results from phase 1 study of EMP-01
- Rising High: Exclusive talk with REIT Healing Realty Trust
